Tumor Necrosis Factor Inhibitors Block Apoptosis of Human Epithelial Cells of the Salivary Glands
- 15 August 2009
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1171 (1) , 407-414
Abstract
Inhibition of tumor necrosis factor‐α (TNF‐α) in organ‐specific autoimmune disease is proving efficacious for a large number of patients. A wide array of biological agents has been designed to inhibit TNF‐α, such as adalimumab (fully humanized) and etanercept (soluble TNF‐α receptor fusion constructs p75 subunit). Recently, we suggested that anti‐Ro and anti‐La autoantibodies (Abs) isolated from patients with Sjögren's syndrome, an autoimmune rheumatic disease, are able to trigger cell death through extrinsic apoptotic mechanisms in human salivary gland epithelial cells (SGEC). We analyzed if primary human SGEC cultures, established from biopsy of labial minor salivary glands, are able to produce TNF‐α, an inductor of the extrinsic apoptotic pathway, when treated with anti‐Ro autoantibodies. A comparative study was performed to test the efficacy of adalimumab and etanercept to block TNF‐α‐mediated apoptosis. ELISA assay and RT‐PCR were employed to visualize TNF‐α production, and apoptosis was evaluated by DNA ladder and flow cytometry. We found that cell treatment with anti‐Ro autoantibodies determines TNF‐α production that reaches a maximum at 16 h and is decreased (P < 0.05) at 24 and 48 h. Adalimumab seems to be more efficacious than etanercept in blocking TNF‐α‐mediated apoptosis. The YOPRO‐1 (+) and propidium iodide (−) method revealed 60% of apoptotic cells after 24 h of incubation with anti‐Ro compared with 15% of apoptotic cells treated with anti‐Ro plus adalimumab and 25% of apoptotic cells treated with anti‐Ro plus etanercept. The antiapoptotic effect of adalimumab and etanercept was supported by inhibition of DNA laddering induced by anti‐Ro Abs. These data validate the therapeutic efficacy of the anti‐TNF reagents in the treatment of autoimmune disorders.Keywords
This publication has 27 references indexed in Scilit:
- Evidence that anti–tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended reportArthritis & Rheumatism, 2005
- The TNF and TNF Receptor SuperfamiliesCell, 2001
- Staphylococcal Toxins and Protein A Differentially Induce Cytotoxicity and Release of Tumor Necrosis Factor–α From Human KeratinocytesJournal of Investigative Dermatology, 1996
- Dimerization of chimeric erythropoietin /75 kDa Tumour Necrosis Factor (TNF) receptors transduces TNF signals: necessity for the 75 kDa-TNF receptor transmembrane domainCytokine, 1995
- Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.Journal of Clinical Investigation, 1995
- A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion.Journal of Clinical Investigation, 1995
- Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an AntigenNature Biotechnology, 1994
- The Pathophysiology of Tumor Necrosis FactorsAnnual Review of Immunology, 1992
- Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes.Journal of Experimental Medicine, 1987
- Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxinInternational Journal of Cancer, 1985